Zoltan Csanadi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7046931/publications.pdf

Version: 2024-02-01

54 papers	6,954 citations	567281 15 h-index	189892 50 g-index
57 all docs	57 docs citations	57 times ranked	7156 citing authors

#	Article	IF	Citations
1	Comparison of management and outcomes of ST-segment elevation myocardial infarction patients in Estonia, Hungary, Norway, and Sweden according to national ongoing registries. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 307-314.	4.0	13
2	The Feasibility of Baroreflex Sensitivity Measurements in Heart Failure Subjects: The Role of Slowâ€patterned Breathing. Clinical Physiology and Functional Imaging, 2022, , .	1.2	0
3	Hypothetical dysfunction of the epithelial sodium channel may justify neurohumoral blockade in coronavirus disease 2019. ESC Heart Failure, 2021, 8, 171-174.	3.1	8
4	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	2.2	5,583
5	The impact of hydrostatic pressure on the result of physiological measurements in various coronary segments. International Journal of Cardiovascular Imaging, 2021, 37, 5-14.	1.5	12
6	Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis: implications for ACE2 as a biomarker for the severity of COVID-19. GeroScience, 2021, 43, 19-29.	4.6	24
7	Predictors of Hospital Mortality in Patients with Acute Coronary Syndrome Complicated by Cardiogenic Shock. Sensors, 2021, 21, 969.	3.8	4
8	Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans. Basic Research in Cardiology, 2021, 116, 24.	5.9	15
9	Cardiopulmonary Resuscitation With Mechanical Chest Compression Device During Percutaneous Coronary Intervention. A Case Report. Frontiers in Cardiovascular Medicine, 2021, 8, 614493.	2.4	0
10	Role of 3D echocardiographyâ€determined atrial volumes in distinguishing between preâ€capillary and postâ€capillary pulmonary hypertension. ESC Heart Failure, 2021, 8, 3975-3983.	3.1	5
11	Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational Modifications, Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart. Cells, 2021, 10, 1708.	4.1	11
12	Sympathetic activation in heart failure with reduced and mildly reduced ejection fraction: the role of aetiology. ESC Heart Failure, 2021, 8, 5112-5120.	3.1	2
13	Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients. GeroScience, 2021, 43, 2289-2304.	4.6	13
14	2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 655-720.	2.2	647
15	Uninterrupted Dabigatran Administration Provides Greater Inhibition against Intracardiac Activation of Hemostasis as Compared to Vitamin K Antagonists during Cryoballoon Catheter Ablation of Atrial Fibrillation. Journal of Clinical Medicine, 2020, 9, 3050.	2.4	2
16	Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy. Journal of Translational Medicine, 2020, 18, 470.	4.4	6
17	Negative Inotropic Effect of BGP-15 on the Human Right Atrial Myocardium. Journal of Clinical Medicine, 2020, 9, 1434.	2.4	4
18	Intracardiac Fibrinolysis and Endothelium Activation Related to Atrial Fibrillation Ablation with Different Techniques. Cardiology Research and Practice, 2020, 2020, 1-8.	1.1	5

#	Article	IF	Citations
19	Pharmacological Overview of the BGP-15 Chemical Agent as a New Drug Candidate for the Treatment of Symptoms of Metabolic Syndrome. Molecules, 2020, 25, 429.	3.8	20
20	Paroxysmal and persistent atrial fibrillation ablation outcomes with the pulmonary vein ablation catheter GOLD duty-cycled phased radiofrequency ablation catheter: quality of life and 12-month efficacy results from the GOLD Atrial Fibrillation Registry. Europace, 2020, 22, 888-896.	1.7	13
21	Three-Dimensional Echocardiographic Method for the Visualization and Assessment of Specific Parameters of the Pulmonary Veins. Journal of Visualized Experiments, 2020, , .	0.3	2
22	Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy. Journal of Translational Medicine, 2019, 17, 229.	4.4	14
23	Quantification of peripheral whole blood, cell-free plasma and exosome encapsulated mitochondrial DNA copy numbers in patients with atrial fibrillation. Journal of Biotechnology, 2019, 299, 66-71.	3.8	19
24	PITX2 and NEURL1 SNP polymorphisms in Hungarian atrial fibrillation patients determined by quantitative real-time PCR and melting curve analysis. Journal of Biotechnology, 2019, 299, 44-49.	3.8	3
25	Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future. European Heart Journal, 2019, 40, 1728-1738.	2.2	8
26	Relationship between cardiovascular diseases and circulating cell-free nucleic acids in human plasma. Biomarkers in Medicine, 2018, 12, 891-905.	1.4	9
27	Initial international multicenter human experience with a novel epicardial access needle embedded with a real-time pressure/frequency monitoring to facilitate epicardial access: Feasibility and safety. Heart Rhythm, 2017, 14, 981-988.	0.7	34
28	Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation. BioMed Research International, 2017, 2017, 1-10.	1.9	17
29	Potential Biological Markers of Atrial Fibrillation: A Chance to Prevent Cryptogenic Stroke. BioMed Research International, 2017, 2017, 1-10.	1.9	13
30	Cerebral micro-embolization during pulmonary vein isolation: Relation to post-ablation silent cerebral ischemia. Cardiology Journal, 2017, 24, 234-241.	1.2	4
31	Circulating ACE2 activity correlates with cardiovascular disease development. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2016, 17, 147032031666843.	1.7	80
32	Atrial Fibrillation Ablation and Stroke. Cardiology Clinics, 2016, 34, 307-316.	2.2	3
33	Low rate of asymptomatic cerebral embolism and improved procedural efficiency with the novel pulmonary vein ablation catheter GOLD: results of the PRECISION GOLD trial. Europace, 2016, 18, 687-695.	1.7	45
34	Phased RF Ablation: Results and Concerns. Journal of Atrial Fibrillation, 2015, 8, 1240.	0.5	5
35	Learning curve in circular multipolar phased radiofrequency ablation of atrial fibrillation. Cardiology Journal, 2015, 22, 260-265.	1.2	12
36	Predictors of Cerebral Microembolization during Phased Radiofrequency Ablation of Atrial Fibrillation: Role of the Ongoing Rhythm and the Site of Energy Delivery. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 1436-1441.	1.2	4

#	Article	IF	Citations
37	Cerebral microembolization during atrial fibrillation ablation: Comparison of different single-shot ablation techniques. International Journal of Cardiology, 2014, 174, 276-281.	1.7	30
38	Predictors of cerebral microembolization during phased radiofrequency ablation of atrial fibrillation: Analysis of biophysical parameters from the ablation generator. Heart Rhythm, 2014, 11, 977-983.	0.7	12
39	Cerebrovascular Complications Related to Atrial Fibrillation Ablation and Strategies for Periprocedural Stroke Prevention. Cardiac Electrophysiology Clinics, 2014, 6, 111-123.	1.7	5
40	New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) IV: Circulating ACE2 as a Biomarker of Systolic Dysfunction in Human Hypertension and Heart Failure. PLoS ONE, 2014, 9, e87845.	2.5	82
41	Electrical Storm in the Brain and in the Heart: Epilepsy and Brugada Syndrome. Mayo Clinic Proceedings, 2013, 88, 1167-1173.	3.0	25
42	Transcranial Measurement of Cerebral Microembolic Signals During Pulmonary Vein Isolation. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 473-480.	4.8	47
43	The Seattle Heart Failure Model Predicts Survival in Patients With Cardiac Resynchronization Therapy: A Validation Study. Journal of Cardiac Failure, 2012, 18, 682-687.	1.7	12
44	Adenosineâ€Dependent Concealed Accessory Pathway. PACE - Pacing and Clinical Electrophysiology, 2012, 35, e91-3.	1.2	4
45	Longâ€term Arrhythmia Variability after Monomorphic Ventricular Tachycardia in Patients with an Implantable Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 1185-1191.	1.2	3
46	Pacemaker-Mediated Tachycardia over the Upper Rate Limit in a Biventricular Pacemaker System: What is the Mechanism?. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 1421-1424.	1.2	4
47	Reduction in Ventricular Pacing After AV Node Modification in a Patient with Dualâ€Chamber Pacemaker: What is the Mechanism?. Journal of Cardiovascular Electrophysiology, 2008, 19, 1116-1117.	1.7	0
48	Radiofrequency catheter ablation of premature ventricular complexes improved left ventricular function in a non-responder to cardiac resynchronization therapy. Europace, 2007, 9, 285-288.	1.7	29
49	Unexpected Consequences of Right Atrium Isthmus Ablation in a Patient After Surgical Closure of an Atrial Septal Defect. Journal of Cardiovascular Electrophysiology, 2006, 17, 216-218.	1.7	1
50	Multiple Reentrant Tachycardias in a Patient with WPW Syndrome. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 429-431.	1.2	1
51	Comparison of Single-Biphasic Versus Sequential-Biphasic Shocks on Defibrillation Threshold in Pigs. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 1606-1612.	1.2	6
52	Complex Arrhythmia Substrate in Supraventricular Tachycardia: Implications for Radiofrequency Ablation. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 496-508.	1.2	0
53	Significance of cycle length alternation during orthodromic atrioventricular reentrant tachycardia. American Journal of Cardiology, 1995, 75, 626-627.	1.6	2
54	Effect of Dual Atrioventricular Node Pathways on Atrioventricular Reentrant Tachycardia. Circulation, 1995, 91, 2614-2618.	1.6	32